| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 09/20/2001 | WO2001068075A2 Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals |
| 09/20/2001 | WO2001068074A2 Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds |
| 09/20/2001 | WO2001068071A2 Use of natural chrysanthone compounds having antiangiogenic activity |
| 09/20/2001 | WO2001068070A2 Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis |
| 09/20/2001 | WO2001068033A2 Il-8 receptor antagonists |
| 09/20/2001 | WO2001028579A3 Inhibitors of proteasomal activity for stimulating bone and hair growth |
| 09/20/2001 | WO2001020018A8 Diagnosing and treating arthritic disorders |
| 09/20/2001 | WO2001019819A3 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 09/20/2001 | WO2001015664A3 Coformulation methods and their products |
| 09/20/2001 | WO2001010427A3 Use of anti-muscarinic agents for treating skin disorders |
| 09/20/2001 | WO2000047583A9 Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 09/20/2001 | WO2000027378A3 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases |
| 09/20/2001 | WO2000009537A3 Compounds having growth hormone releasing activity |
| 09/20/2001 | US20010023250 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| 09/20/2001 | EP1143960A3 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases |
| 09/20/2001 | CA2403679A1 Il-8 receptor antagonists |
| 09/20/2001 | CA2403393A1 Methods and compositions for immunoregulation |
| 09/20/2001 | CA2403189A1 Inflammation-inducible hybrid promoters, vectors containing same and uses thereof |
| 09/20/2001 | CA2403120A1 Method for in vitro production of three-dimensional vital cartilage or bone tissue and use thereof as transplant material |
| 09/20/2001 | CA2403084A1 A method for reversing the immunosuppressive effects of the melanoma inhibitory activity "mia" |
| 09/20/2001 | CA2403063A1 Polysaccharidic esters of n-derivatives of glutamic acid |
| 09/20/2001 | CA2403062A1 Il-8 receptor antagonists |
| 09/20/2001 | CA2403017A1 5-amide substituted diarylamines as mex inhibitors |
| 09/20/2001 | CA2402891A1 Il-8 receptor antagonists |
| 09/20/2001 | CA2402559A1 Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds |
| 09/20/2001 | CA2402549A1 Substituted beta-carbolines |
| 09/20/2001 | CA2402427A1 Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-a]pyrimidines as antidepressant agents |
| 09/20/2001 | CA2402413A1 Compositions and methods for affecting osteogenesis |
| 09/20/2001 | CA2401448A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 09/20/2001 | CA2401267A1 Use of natural compounds having antiangiogenic activity |
| 09/20/2001 | CA2400106A1 Antibodies to human cd154 |
| 09/19/2001 | EP1134286A2 Adamts polypeptides, nucleic acids encoding them, and uses thereof |
| 09/19/2001 | EP1134215A1 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases |
| 09/19/2001 | EP1133997A2 Treatment of immune diseases with beta-interferon |
| 09/19/2001 | EP1133994A1 A method for reversing the immunosuppressive effects of the Melanoma Inhibitory Activity "MIA" |
| 09/19/2001 | EP1133560A1 Human parathyroid hormone modifications, preparation and use |
| 09/19/2001 | EP1133558A1 Compositions and methods for increasing bone mineralization |
| 09/19/2001 | EP1133557A2 Growth factor modulators |
| 09/19/2001 | EP1133517A1 INTRACELLULAR TARGETED DELIVERY OF COMPOUNDS BY 70 kD HEAT SHOCK PROTEIN |
| 09/19/2001 | EP1133491A1 Novel benzofurane derivatives, preparation method, use as medicines and pharmaceutical compositions containing same |
| 09/19/2001 | EP1133488A1 Propanoic acid derivatives as integrin inhibitors |
| 09/19/2001 | EP1133486A2 Nonsteroidal antiinflammatories |
| 09/19/2001 | EP1133484A2 Heterocyclic derivatives and their use as integrin inhibitors |
| 09/19/2001 | EP1133481A1 Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors |
| 09/19/2001 | EP1133480A1 Quinoline and quinoxaline compounds as pdgf-receptor and/or lck tyrosine kinase inhibitors |
| 09/19/2001 | EP1133478A1 Novel acylguanidine derivatives, method for preparing same, application as medicines and pharmaceutical compositions containing them |
| 09/19/2001 | EP1133476A1 Iminoguanidine derivatives, preparation method, use as medicines |
| 09/19/2001 | EP1133471A1 Hydrazine derivatives |
| 09/19/2001 | EP1133317A1 Transport system conjugate |
| 09/19/2001 | EP1133315A1 Antagonists of the alpha e beta 7 integrin as therapeutic agents for inflammatory diseases |
| 09/19/2001 | EP0923529B1 Substitute 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors |
| 09/19/2001 | CN1313863A Inhibitors of urokinase and blood vessel fomation |
| 09/19/2001 | CN1313862A Novel 17-halogenated 19-Nor steroids, method and intermediates for preparing same, use as medicines and pharmaceutical compositions containing same |
| 09/19/2001 | CN1313855A Inhibitors of alpha4Betal mediated cell adhesion alpha Beta |
| 09/19/2001 | CN1313769A Pharmaceutical combination comprising A COX-2 inhibitor and a iNOS inhibitor |
| 09/19/2001 | CN1313116A Kangpi capsule |
| 09/19/2001 | CN1313105A 'Chinese-medicinal pad' and its preparing process |
| 09/19/2001 | CN1313100A Powdered medicine for treating bone injury |
| 09/19/2001 | CN1313095A Process for preparing plaster to promote circulation of blood and vital energy |
| 09/19/2001 | CN1071329C Aryl glycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds |
| 09/19/2001 | CN1071328C Arginine angalogues having nitric oxide synthase inhibitor activity |
| 09/19/2001 | CN1071130C Preparation used for orthopedics and its preparing process |
| 09/19/2001 | CA2372450A1 Liquid injectable formulation of disodium pamidronate |
| 09/18/2001 | US6291523 Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives |
| 09/18/2001 | US6291522 Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents |
| 09/18/2001 | US6291516 Contacting the cell with a composition including at least one cyclic amp agonist. |
| 09/18/2001 | US6291508 Potent ability to bind to retinoic acid receptors thus useful in treating psoriasis and rheumatoid arthritis. |
| 09/18/2001 | US6291505 Pyrazole estrogen receptor agonist and antagonist |
| 09/18/2001 | US6291503 β-phenylalanine derivatives as integrin antagonists |
| 09/18/2001 | US6291484 Treatment of the various medical conditions associated with postmenopausal syndrome |
| 09/18/2001 | US6291459 Calcilytic compounds |
| 09/18/2001 | US6291457 Compounds having cytokine inhibitory activity |
| 09/18/2001 | US6291456 Compounds and methods for modulation of estrogen receptors |
| 09/18/2001 | US6291451 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| 09/18/2001 | US6291450 Carboxylic acid substituted heterocycles, derivatives thereof and methods of use |
| 09/18/2001 | US6291425 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 09/18/2001 | US6289745 High temperature insertion type flow element and mounting extension |
| 09/15/2001 | WO2001066747A2 Proteins named fctrx and nucleic acids encoding same |
| 09/15/2001 | CA2401552A1 Proteins named fctrx and nucleic acids encoding same |
| 09/13/2001 | WO2001066746A2 G-protein coupled receptor related polypeptides |
| 09/13/2001 | WO2001066742A2 G-protein coupled receptors |
| 09/13/2001 | WO2001066722A1 Immune system-related polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | WO2001066716A1 Polypeptide having phosphodiesterase activity |
| 09/13/2001 | WO2001066601A1 Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals |
| 09/13/2001 | WO2001066597A2 Inflammation-related gene |
| 09/13/2001 | WO2001066594A2 Human protein kinases and protein kinase-like enzymes |
| 09/13/2001 | WO2001066557A1 Adam polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | WO2001066139A1 Use of a compound that selectively binds to cd123 to impair hematologic cancer progenitor cell |
| 09/13/2001 | WO2001066125A1 DNA ENCODING HUMAN ACID-SENSING ION CHANNEL BNaC4 (ASIC4) |
| 09/13/2001 | WO2001066107A2 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 09/13/2001 | WO2001066099A2 Use of quinazoline derivatives as angiogenesis inhibitors |
| 09/13/2001 | WO2001066089A2 Pharmaceutical compositions comprising cannabis |
| 09/13/2001 | WO2001016180A3 Cd40 agonist compositions and methods of use |
| 09/13/2001 | WO2001009169A3 Cysteine protease inhibitors |
| 09/13/2001 | WO2001009138A3 Chemokine receptor antagonists and methods of use therefor |
| 09/13/2001 | US20010021719 2-phenyl-1- [4- (2-aminoethoxy) - benzyl] - indoles as estrogenic agents |
| 09/13/2001 | US20010021695 Administering neurotoxins of botulinum toxin types in an amount to control the duration of therapeutic activity |
| 09/13/2001 | US20010021516 An isolated nucleic acid molecule comprising a polynucleotide having nucleotide sequence atleast 95% identical to a sequence selected from a nucleotide sequence encoding a TRID polypeptide having specific amino acid sequence |
| 09/13/2001 | DE10010113A1 Isolation of collagen by extraction from sponge, giving product having cyclooxygenase inhibiting activity, useful for treating inflammatory diseases such as arthritis or skin inflammation |
| 09/13/2001 | CA2402081A1 A compound that selectively binds to cd123 and use thereof to kill hematologic cancer progenitor cells |